The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | Addressing uncertainty in cystic lung lesion diagnosis and management
Matthew Evison, MD, MRCP, Manchester University Hospital NHS Foundation Trust, Manchester, UK, describes the challenges of managing cystic lesions in lung cancer, highlighting the difficulties in determining whether they are cancerous or benign, and the need for standardized terminology and classification. It is, therefore, important to screen patients and produce consensus statements, which will hopefully lead to further research and improved management of these lesions. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that’s right at the heart of this issue. With cystic lesions, we could be really worried something is cancerous and go ahead for an operation and remove it to find out that it’s benign. And we could think a cystic lesion is benign and watch it and wait and then only later intervene and find out it was a cancer and look back and see that we’ve been watching a cancer for a period of time so that there isn’t an answer for us right now uh and that’s why it’s so important screening is now picking up so many of these lesions and it really resonates with clinical teams everybody we’ve spoken to across this conference is seeing this, is seeing this entity...
I think that’s right at the heart of this issue. With cystic lesions, we could be really worried something is cancerous and go ahead for an operation and remove it to find out that it’s benign. And we could think a cystic lesion is benign and watch it and wait and then only later intervene and find out it was a cancer and look back and see that we’ve been watching a cancer for a period of time so that there isn’t an answer for us right now uh and that’s why it’s so important screening is now picking up so many of these lesions and it really resonates with clinical teams everybody we’ve spoken to across this conference is seeing this, is seeing this entity. And so BTOG are producing this work program. They’re going to produce some consensus statements, which for me is really only the first step. Can we start to use the same names? Can we just use the same term for this entity across all the clinical teams? Can we start to classify it in the same way and uh and that’s really just the first steps and I hope this leads to much more research into these lesions so we can be at another BTOG conference and we can describe exactly when do we intervene on these lesions how do we best manage
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
